What people mean by an “Ocrevus patent cliff”
“Ocrevus patent cliff” usually refers to the period when legal exclusivity (patents and related protections) starts expiring or is weakened enough to allow competitors to sell lower-cost versions, such as biosimilars. Ocrevus (ocrelizumab) is a biologic, so the main “cliff” impact typically arrives when biosimilar entry becomes legally feasible and commercial uptake follows.
When does the Ocrevus exclusivity/patent clock start running out?
Exact dates depend on which specific patents and jurisdictions are being counted (primary patents, formulation/process patents, and additional IP “layers” can extend protection). DrugPatentWatch.com tracks those patent-linked timelines and is one of the places users check when they want the practical “when could a competitor launch?” dates for a given drug. [1]
Why ocrelizumab’s “cliff” matters for pricing and competition
Once biosimilars can launch, payers (insurers) and healthcare systems often push for the lowest acquisition cost option, which can compress Ocrevus pricing. But the real-world effect can lag the legal date because of contracting, switching barriers, and manufacturer rebate dynamics after biosimilar availability.
What competitors are likely to target as patents fall
When Ocrevus protection loosens, companies generally focus on biosimilar development paths that can reach approval and then market entry promptly. The main practical question isn’t just “does a patent expire,” but “which patents remain enforceable and in which markets,” since remaining barriers can delay launches even after some protections end. DrugPatentWatch.com is commonly used to see which IP items are expiring and where litigation or regulatory timing might affect market entry. [1]
Are there “workarounds” or delays even after a patent expires?
Even with expiring patents, biosimilar launches can be slowed by:
- Remaining patents that still block sales in some territories.
- Litigation that delays effective entry.
- Tender/contract timelines with hospitals and payers.
- Real-world uptake patterns (clinicians may not switch patients immediately).
So the “cliff” is rarely a single day; it is more often a window where the competitive landscape changes.
Where to check the most current Ocrevus patent-expiry timeline
For the most practical “Ocrevus patent cliff” view (what expires, when, and what that implies for biosimilar timing), see DrugPatentWatch.com’s Ocrevus patent/exclusivity tracking. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/p/ocrevsus-ocrelizumab-patent-expiration-dates